Vacuum-Assisted Breast Biopsy Device Market Updates

Global Vacuum-Assisted Breast Biopsy Device Market size was valued at USD 811.85 million in 2023 and is poised to grow from USD 906.84 million in 2024 to USD 2197.63 million by 2032, growing at a CAGR of 11.7% during the forecast period (2025-2032).

The market is dominated by Becton Dickinson and Co (Bd), Devicor Medical Products Inc (Mammotome) and Hologic Inc. Key players in the vacuum-assisted breast biopsy device market are adopting strategies like product launch, merger, and acquisition, and high R&D investments to gain a significant market share. For instance, In March 2021, IZI Medical Products, LLC launched The Quick-Core Auto Biopsy System ("Quick-Core Auto") for soft tissue biopsy. Quick-Core Auto is a lightweight, fully automatic biopsy system that offers the precision, dependability, and quality of IZI's Quick-Core semi-automatic biopsy system. 'Hologic, Inc. (USA) ', 'BD (Becton, Dickinson and Company) (USA) ', 'Siemens Healthineers (Germany) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Argon Medical Devices, Inc. (USA) ', 'Cook Medical (USA) ', 'Stryker Corporation (USA) ', 'Cardinal Health, Inc. (USA) ', 'Medtronic plc (Ireland) ', 'Canon Medical Systems Corporation (Japan) ', 'FUJIFILM Holdings Corporation (Japan) ', 'Boston Scientific Corporation (USA) ', 'Johnson & Johnson (USA) ', 'AngioDynamics, Inc. (USA) ', 'Merit Medical Systems, Inc. (USA)'

Vacuum-assisted breast biopsy (VABB) devices are gaining immense popularity over conventional biopsy methods because of their ability to obtain large number of tissues with contiguous specimens, the possibility of acquiring multiple specimens with single insertion of a needle, a more accurate diagnosis with a lower cancer miss rate and lower histological underestimates. Apart from the diagnostic indications, VABB is also a recognized method of therapeutic removal of benign lesions such as fibroadenomas. The use of percutaneous VABB can reduce the need for open surgical biopsy or excision, and minimize costs of the operating theatre or hospital stays associated with surgical excision. Hence, all of these factors are driving the growth of Vacuum-assisted breast biopsy (VABB) devices.

The vacuum-assisted breast biopsy device market is growing as a result of a broad and vigorous research environment, which has contributed to the development of more accurate and minimally invasive treatments for the early detection of breast cancer. Governments have also attempted to create a stable and all-encompassing environment for cancer research, which has aided in the development of these diagnostic devices.

The North America region dominates the global vacuum-assisted breast biopsy device market and is projected to maintain a similar trend over the forecast period. North America's vacuum-assisted breast biopsy device market is projected to grow at a CAGR of 4.4% over the forecast period. The US is also the fastest growing country in the region followed by Canada. Each year, over 1 million breast biopsies are performed in the United States, The American Cancer Society, advises women to participate in self-awareness exams held throughout the year, which help individuals detect any changes in their breast that would be further diagnosed by a physician. Moreover, among all the region, The Asia pacific region is fastest growing market. There has been an exponential rise in breast cancer cases in Asian countries over the last few decades. According to a study on breast cancer in Asia, breast cancer mortality increased among Asian women due to a higher prevalence of breast cancer risk factors such as delayed childbirth, and increased obesity.